Patricia Coyle, MD: Multiple Sclerosis Symptom Management
Ensuring patients quality of life is still being attended to is of utmost importance to the director of the Comprehensive Multiple Sclerosis Center at Stony Brook University.
Staying Knowledgeable, Reducing Stigma of Pediatric Epilepsy
The Medical Director of Neurology and Justin Neurosciences Center at Cook Children's Medical Center spoke about the importance of staying up-to-date and informed about this rapidly changing space.
Guideline Update: Disorders of Consciousness
Practice guidelines for the management of low-level, minimally conscious states resulting from brain injury include recommendations for assessment, treatment protocol, and supportive approaches.
Howard Fillit, MD: Alzheimer Disease Drug Development Improvement
The ADDF's founding executive director and chief scientific officer spoke about the gains in clinical trials in the last 5 years.
Allogeneic Mesenchymal Stem Cells Under Exploration for Alzheimer Disease, Aging Frailty
Allogeneic mesenchymal stem cells manufactured by Longeveron are advancing through phase I and II clinical trials.
Ronald Crystal, MD: APOE2 Gene Therapy for Alzheimer Disease
The chairman of the Department of Genetic Medicine at Weill Cornell Medicine shared his experience with the therapy and its potential in the space.
For Mild Cognitive Impairment, Behavioral Activation Outperforms Supportive Therapy
Memory decline was worse for patients with MCI receiving supportive therapy over behavioral activation.
Treating and Identifying Large Vessel Occlusion Quickly
The assistant professor of neurology and neurosurgery spoke about the need to identify LVO in the field, quickly, to improve care.
Patricia Coyle, MD: Needed Improvements in Multiple Sclerosis
The director of the Comprehensive Multiple Sclerosis Center at Stony Brook Neuroscience Institute discussed these needs.
XEN496 for KCNQ2 Epileptic Encephalopathy, the State of Acute Stroke Care, and Ocrelizumab's Success
Neurology News Network for the week of September 15, 2018.
Communication and Cooperation in Epilepsy Care
The director of the Epilepsy Program at the Banner University Medical Center spoke about the importance of interaction between general neurology and epileptologists.
FDA Approves Fremanezumab for Migraine Prevention
The monoclonal antibody is now the second member of the CGRP inhibitor class to be approved by the FDA.
Biohaven Submits IND for Migraine Therapy BHV-3500
The third-generation, small molecule CGRP antagonist is the second Biohaven migraine therapy to reach human clinical development.
Pediatric Epilepsy, Treating the Whole Patient
Jason Lerner MD, discussed the recently opened Adolescent Epilepsy Center at UCLA, a clinic that offers comprehensive care for teens with epilepsy.
Phase II Trial of Trans Sodium Crocetinate in Acute Stroke Endorsed by FDA
TSC has shown potential to become the first approved therapy for acute stroke, able to be administered in the ambulance.
Fingolimod Lowers Relapse Rates, MRI Lesion Accumulation in Pediatric Patients
After its approval in May for pediatric MS, the data displayed its efficacy in comparison to standard therapy.
DHE As An Acute Migraine Therapy Post-Preventive Approvals
The director of the Dartmouth Headache Clinic at Dartmouth-Hitchcock Medical Center spoke about the potential of a DHE therapy for acute migraine treatment.
Drugs and Creativity: Fact or Fiction?
Creativity, a human ability that provides artistic, organizational, and scientific innovation, moves the world forward. Do drugs that alter perception help or hinder that process?
ALS-Specific Cognitive, Behavioral Changes Associated with Advancing Disease Stage
The relationship between disease stage and behavior is important given the strength of the relationship relative to cognition and its negative impact on patients and caregivers.
Pitolisant Reduces ESS Scores Up to 5 Years in Patients with Excessive Daytime Sleepiness
By the open-label extension’s end, those treated with pitolisant showed a decrease in ESS score by 6.2 from baseline.
The Recent Revolution in Acute Stroke Care
The co-director of the UPMC’s Center for Endovascular Therapy spoke about the gains that stroke care has made in the last few years.
Clearing Up Confusion About Cannabidiol for Dravet Syndrome
The idea of marijuana as a panacea for neurologic conditions has come into play, leading to a need for clarification about the use of CBD for these conditions.
Insomnia Treatment Moving Toward Precision Medicine
Rachel Salas, MD, a Johns Hopkins Associate Professor, spoke about insomnia, a very individualized disorder, and the need for moving toward precision medicine.
Early Monitoring of Antiepileptic Drugs Could Prevent Increased Seizure Frequency During Pregnancy
Study findings revealed that AED clearance significantly changes by the first trimester for levetiracetam and by the second trimester for oxcarbazepine and topiramate.
Reintroducing DHE for Acute Migraine Treatment
As a phase III trial of DHE gets underway, the director of the Dartmouth Headache Clinic at Dartmouth-Hitchcock Medical Center spoke about its clinical history in the United States.
Patricia K. Coyle, MD: Early Multiple Sclerosis Identification
The director of the Comprehensive Multiple Sclerosis Center at Stony Brook Neuroscience Institute spoke about the importance of early treatment and identification of the condition.
Multiple Sclerosis Disability Evolution Risk Profile Informs Personalized Treatment
A real-world study in relapsing MS helped develop a risk score scale to aid in disability progression prediction, and thus, treatment strategies.
Fred Lublin, MD: Beginning to Treat Progressive Multiple Sclerosis
The MS expert discussed the field's recent foray into treating progressive forms of the disease and what is in development.
XEN496 Being Developed for KCNQ2 Epileptic Encephalopathy
Xenon Pharmaceuticals announced the expansion of its ion channel pipeline as a result of feedback from the FDA.
Striving for Full Seizure Control in Epilepsy, LGS, Dravet Syndrome
The director of the Epilepsy Program at the Banner University Medical Center spoke about the needs in patient populations with epilepsy.
